{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:56:33Z","timestamp":1787885793895,"version":"build-2784847793"},"publisher-location":"Cham","reference-count":92,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031180699","type":"print"},{"value":"9783031180705","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/82_2022_259","type":"book-chapter","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T19:04:05Z","timestamp":1659121445000},"page":"167-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Development of mRNA Vaccines: Challenges and Opportunities"],"prefix":"10.1007","author":[{"given":"Allison","family":"August","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Zaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"issue":"10101","key":"259_CR1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","volume":"390","author":"M Alberer","year":"2017","unstructured":"Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G et al (2017a) Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390(10101):1511\u20131520","journal-title":"Lancet"},{"issue":"8","key":"259_CR3","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","volume":"39","author":"C Aldrich","year":"2021","unstructured":"Aldrich C, Leroux-Roels I, Huang KB, Bica MA, Loeliger E, Schoenborn-Kellenberger O et al (2021) Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial. Vaccine 39(8):1310\u20131318","journal-title":"Vaccine"},{"issue":"3","key":"259_CR4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.coi.2012.03.008","volume":"24","author":"CR Alving","year":"2012","unstructured":"Alving CR, Peachman KK, Rao M, Reed SG (2012) Adjuvants for human vaccines. Curr Opin Immunol 24(3):310\u2013315","journal-title":"Curr Opin Immunol"},{"issue":"25","key":"259_CR5","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","volume":"383","author":"EJ Anderson","year":"2020","unstructured":"Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M et al (2020) Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 383(25):2427\u20132438","journal-title":"N Engl J Med"},{"key":"259_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","volume":"217","author":"O Andries","year":"2015","unstructured":"Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T (2015) N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release 217:337\u2013344","journal-title":"J Control Release"},{"key":"259_CR7","unstructured":"Arcturus therapeutics reports new data demonstrating neutralizing antibody immune response to the SARS-CoV-2 Omicron variant from ARCT-154 and ARCT-165 booster clinical trial [press release] (2022)"},{"issue":"12","key":"259_CR8","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","volume":"27","author":"A August","year":"2021","unstructured":"August A, Attarwala HZ, Himansu S, Kalidindi S, Lu S, Pajon R et al (2021) A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat Med 27(12):2224\u20132233","journal-title":"Nat Med"},{"issue":"5","key":"259_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384(5):403\u2013416","journal-title":"N Engl J Med"},{"issue":"1","key":"259_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1128\/JVI.01786-15","volume":"90","author":"M Brazzoli","year":"2015","unstructured":"Brazzoli M, Magini D, Bonci A, Buccato S, Giovani C, Kratzer R et al (2015) Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. J Virol 90(1):332\u2013344","journal-title":"J Virol"},{"issue":"12","key":"259_CR12","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1038\/mt.2014.133","volume":"22","author":"LA Brito","year":"2014","unstructured":"Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M et al (2014) A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther 22(12):2118\u20132129","journal-title":"Mol Ther"},{"key":"259_CR13","doi-asserted-by":"crossref","unstructured":"Burny W, Callegaro A, Bechtold V, Clement F, Delhaye S, Fissette L et al (2017) Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans. Front Immunol 8(943)","DOI":"10.3389\/fimmu.2017.00943"},{"key":"259_CR14","doi-asserted-by":"crossref","unstructured":"Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D (2021) Nanomaterial delivery systems for mRNA vaccines. Vaccines (Basel) 9(1)","DOI":"10.3390\/vaccines9010065"},{"issue":"1","key":"259_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/nyas.14235","volume":"1462","author":"J Cable","year":"2020","unstructured":"Cable J, Srikantiah P, Crowe JE Jr, Pulendran B, Hill A, Ginsberg A et al (2020) Vaccine innovations for emerging infectious diseases-a symposium report. Ann N Y Acad Sci 1462(1):14\u201326","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"259_CR16","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC et al (2020) mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Investig 130(11):5976\u20135988","journal-title":"J Clin Investig"},{"key":"259_CR17","unstructured":"Centers for Disease Control and Prevention (2020) Adjuvants and vaccines 2020 [updated January 25. Available from: https:\/\/www.cdc.gov\/vaccinesafety\/concerns\/adjuvants.html"},{"key":"259_CR18","unstructured":"Centers for Disease Control and Prevention. COVID data tracker 2022 [updated Jan 25]. Available from: https:\/\/covid.cdc.gov\/covid-data-tracker"},{"key":"259_CR19","doi-asserted-by":"crossref","unstructured":"Chapin-Bardales J, Gee J, Myers T (2021) Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA 325(21):2201\u20132202","DOI":"10.1001\/jama.2021.5374"},{"key":"259_CR20","doi-asserted-by":"crossref","unstructured":"Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B et al (2021) A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine 39(20):2791\u20132799","DOI":"10.1016\/j.vaccine.2021.02.007"},{"issue":"4","key":"259_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33(4):492\u2013503","journal-title":"Immunity"},{"key":"259_CR22","unstructured":"Comirnaty and Pfizer-BioNTech COVID-19 vaccine [press release] (2021)"},{"issue":"7830","key":"259_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA et al (2020a) SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586(7830):567\u2013571","journal-title":"Nature"},{"key":"259_CR24","unstructured":"Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP et al (2020b) Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med 383(16):1544\u20131555"},{"key":"259_CR25","doi-asserted-by":"crossref","unstructured":"Corbett KS, Nason MC, Flach B, Gagne M, O\u2019Connell S, Johnston TS et al (2021) Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 373(6561):eabj0299","DOI":"10.1126\/science.abj0299"},{"issue":"7","key":"259_CR26","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"PR Cullis","year":"2017","unstructured":"Cullis PR, Hope MJ (2017) Lipid nanoparticle systems for enabling gene therapies. Mol Ther 25(7):1467\u20131475","journal-title":"Mol Ther"},{"issue":"11","key":"259_CR27","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J et al (2016) Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 375(11):1019\u20131032","journal-title":"N Engl J Med"},{"issue":"7","key":"259_CR28","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1080\/21645515.2015.1043501","volume":"11","author":"FT Da Silva","year":"2015","unstructured":"Da Silva FT, Di Pasquale A, Yarzabal JP, Garcon N (2015) Safety assessment of adjuvanted vaccines: methodological considerations. Hum Vaccin Immunother 11(7):1814\u20131824","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"259_CR29","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1517\/17425247.2014.901308","volume":"11","author":"RP Deering","year":"2014","unstructured":"Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ (2014) Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Deliv 11(6):885\u2013899","journal-title":"Expert Opin Drug Deliv"},{"key":"259_CR30","doi-asserted-by":"crossref","unstructured":"Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303(5663):1529\u20131531","DOI":"10.1126\/science.1093616"},{"issue":"2","key":"259_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.4049\/jimmunol.175.2.633","volume":"175","author":"JJ Donnelly","year":"2005","unstructured":"Donnelly JJ, Wahren B, Liu MA (2005) DNA vaccines: progress and challenges. J Immunol 175(2):633\u2013639","journal-title":"J Immunol"},{"key":"259_CR32","doi-asserted-by":"crossref","unstructured":"Doria-Rose N, Suthar MS, Makowski M, O\u2019Connell S, McDermott AB, Flach B et al (2021) Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med 384(23):2259\u20132261","DOI":"10.1056\/NEJMc2103916"},{"issue":"5","key":"259_CR33","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.4049\/jimmunol.165.5.2850","volume":"165","author":"M Dupuis","year":"2000","unstructured":"Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M et al (2000) Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 165(5):2850\u20132858","journal-title":"J Immunol"},{"issue":"32","key":"259_CR34","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR et al (2021) Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39(32):4423\u20134428","journal-title":"Vaccine"},{"key":"259_CR10","doi-asserted-by":"crossref","unstructured":"El Sahly HM et al (2021) Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med 385:1774\u20131785","DOI":"10.1056\/NEJMoa2113017"},{"key":"259_CR35","unstructured":"FDA Approves First COVID-19 vaccine: Approval Signifies Key Achievement for Public Health [press release] (2021)"},{"key":"259_CR36","doi-asserted-by":"crossref","unstructured":"Feldman RA, Fuhr R, Smolenov I, Mick Ribeiro A, Panther L, Watson M et al (2019) mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37(25):3326\u20133334","DOI":"10.1016\/j.vaccine.2019.04.074"},{"issue":"27","key":"259_CR37","doi-asserted-by":"publisher","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","volume":"70","author":"JW Gargano","year":"2021","unstructured":"Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME et al (2021) Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices\u2014United States, June 2021. MMWR Morb Mortal Wkly Rep 70(27):977\u2013982","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"36","key":"259_CR38","doi-asserted-by":"publisher","first-page":"14604","DOI":"10.1073\/pnas.1209367109","volume":"109","author":"AJ Geall","year":"2012","unstructured":"Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K et al (2012) Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA 109(36):14604\u201314609","journal-title":"Proc Natl Acad Sci USA"},{"key":"259_CR39","doi-asserted-by":"crossref","unstructured":"Gilbert PB, Montefiori DC, McDermott A, Fong Y, Benkeser D, Deng W et al (2021) Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375(6576):43\u201350. https:\/\/doi.org\/10.1126\/science.abm3425","DOI":"10.1126\/science.abm3425"},{"issue":"14","key":"259_CR40","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jama.2018.0345","volume":"319","author":"BS Graham","year":"2018","unstructured":"Graham BS, Mascola JR, Fauci AS (2018) Novel vaccine technologies: essential components of an adequate response to emerging viral diseases. JAMA 319(14):1431\u20131432","journal-title":"JAMA"},{"key":"259_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","volume":"15","author":"KJ Hassett","year":"2019","unstructured":"Hassett KJ, Benenato KE, Jacquinet E, Lee A, Woods A, Yuzhakov O et al (2019) Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acids 15:1\u201311","journal-title":"Mol Ther Nucleic Acids"},{"key":"259_CR42","doi-asserted-by":"crossref","unstructured":"Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA et al (2013) Rapidly produced SAM\u00ae vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2(8):e52","DOI":"10.1038\/emi.2013.54"},{"issue":"2","key":"259_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41569-021-00662-w","volume":"19","author":"S Heymans","year":"2022","unstructured":"Heymans S, Cooper LT (2022) Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms. Nat Rev Cardiol 19(2):75\u201377","journal-title":"Nat Rev Cardiol"},{"issue":"13","key":"259_CR44","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","volume":"108","author":"S Holtkamp","year":"2006","unstructured":"Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C et al (2006) Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108(13):4009\u20134017","journal-title":"Blood"},{"key":"259_CR45","doi-asserted-by":"crossref","unstructured":"Husby A, Hansen JV, Fosbol E, Thiesson EM, Madsen M, Thomsen RW, et al (2021) SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ 375:e068665","DOI":"10.1136\/bmj-2021-068665"},{"key":"259_CR46","doi-asserted-by":"crossref","unstructured":"Izurieta HS, Lu M, Kelman J, Lu Y, Lindaas A, Loc J et al (2020) Comparative effectiveness of influenza vaccines among U.S. Medicare beneficiaries ages 65 years and older during the 2019\u201320 season. Clin Infect Dis 73(11):e4251\u2013e4259","DOI":"10.1093\/cid\/ciaa1727"},{"key":"259_CR47","doi-asserted-by":"crossref","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN et al (2020) An mRNA vaccine against SARS-CoV-2\u2014preliminary report. N Engl J Med 383(20):1920\u20131931","DOI":"10.1056\/NEJMoa2022483"},{"issue":"12","key":"259_CR48","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","volume":"36","author":"S John","year":"2018","unstructured":"John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw CA et al (2018) Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine 36(12):1689\u20131699","journal-title":"Vaccine"},{"issue":"8","key":"259_CR49","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J et al (2015) A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"2","key":"259_CR50","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Kariko","year":"2005","unstructured":"Kariko K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23(2):165\u2013175","journal-title":"Immunity"},{"issue":"11","key":"259_CR51","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3 K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S et al (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16(11):1833\u20131840","journal-title":"Mol Ther"},{"issue":"6","key":"259_CR52","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1586\/eri.11.51","volume":"9","author":"JM Katz","year":"2011","unstructured":"Katz JM, Hancock K, Xu X (2011) Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther 9(6):669\u2013683","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"7","key":"259_CR53","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA et al (2021) Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27(7):1205\u20131211","journal-title":"Nat Med"},{"key":"259_CR54","doi-asserted-by":"crossref","unstructured":"Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R et al (2021) Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial. Lancet Infect Dis 22(3):329\u2013340","DOI":"10.2139\/ssrn.3911826"},{"issue":"17","key":"259_CR55","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1097\/QAD.0000000000002026","volume":"32","author":"L Leal","year":"2018","unstructured":"Leal L, Guardo AC, Mor\u00f3n-L\u00f3pez S, Salgado M, Mothe B, Heirman C et al (2018) Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. AIDS (London, England) 32(17):2533\u20132545","journal-title":"AIDS (London, England)"},{"issue":"12","key":"259_CR56","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","volume":"25","author":"F Liang","year":"2017","unstructured":"Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Rohss J et al (2017) Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol Ther 25(12):2635\u20132647","journal-title":"Mol Ther"},{"key":"259_CR57","doi-asserted-by":"crossref","unstructured":"Liu MA, Fu TM, Donnelly JJ, Caulfield MJ, Ulmer JB (1998) DNA vaccines. Mechanisms for generation of immune responses. Adv Exp Med Biol 452:187\u201391","DOI":"10.1007\/978-1-4615-5355-7_21"},{"key":"259_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0065-2660(05)55002-8","volume":"55","author":"MA Liu","year":"2005","unstructured":"Liu MA, Ulmer JB (2005) Human clinical trials of plasmid DNA vaccines. Adv Genet 55:25\u201340","journal-title":"Adv Genet"},{"key":"259_CR59","doi-asserted-by":"crossref","unstructured":"Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS et al (2021) Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination. Pediatrics 148(3):e2021052478","DOI":"10.1542\/peds.2021-052478"},{"issue":"1","key":"259_CR60","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/vaccines3010090","volume":"3","author":"PD Minor","year":"2015","unstructured":"Minor PD (2015) Assaying the potency of influenza vaccines. Vaccines 3(1):90\u2013104","journal-title":"Vaccines"},{"key":"259_CR61","doi-asserted-by":"crossref","unstructured":"Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L et al (2021) Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military. JAMA Cardiol 6(10):1202\u20131206","DOI":"10.1001\/jamacardio.2021.2833"},{"key":"259_CR62","doi-asserted-by":"crossref","unstructured":"Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O et al (2021) Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination. Immunity 54(9):2133\u20132142","DOI":"10.1016\/j.immuni.2021.08.001"},{"issue":"7644","key":"259_CR63","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR et al (2017) Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543(7644):248\u2013251","journal-title":"Nature"},{"issue":"4","key":"259_CR64","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D (2018a) mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discov 17(4):261\u2013279","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"259_CR65","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1038\/s41467-018-05482-0","volume":"9","author":"N Pardi","year":"2018","unstructured":"Pardi N, Parkhouse K, Kirkpatrick E, McMahon M, Zost SJ, Mui BL et al (2018b) Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat Commun 9(1):3361","journal-title":"Nat Commun"},{"issue":"6","key":"259_CR66","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1084\/jem.20171450","volume":"215","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L et al (2018c) Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med 215(6):1571\u20131588","journal-title":"J Exp Med"},{"key":"259_CR67","doi-asserted-by":"crossref","unstructured":"Pegu A, O\u2019Connell S, Schmidt SD, O\u2019Dell S, Talana CA, Lai L et al (2021) Durability of mRNA-1273 vaccine\u2013induced antibodies against SARS-CoV-2 variants. Science 373(6561):1372\u20131377","DOI":"10.1101\/2021.05.13.444010"},{"issue":"10","key":"259_CR68","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","volume":"198","author":"T Pepini","year":"2017","unstructured":"Pepini T, Pulichino AM, Carsillo T, Carlson AL, Sari-Sarraf F, Ramsauer K et al (2017) Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J Immunol 198(10):4012\u20134024","journal-title":"J Immunol"},{"key":"259_CR69","doi-asserted-by":"crossref","unstructured":"Peter G, des Vignes-Kendrick M, Eickhoff TC, Fine A, Galvin V, Levine MM et al (1999) Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee. Pediatrics 104(4 Pt 1):942\u2013950","DOI":"10.1542\/peds.104.4.942"},{"issue":"12","key":"259_CR70","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/nbt.2436","volume":"30","author":"B Petsch","year":"2012","unstructured":"Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D et al (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30(12):1210\u20131216","journal-title":"Nat Biotechnol"},{"issue":"3","key":"259_CR71","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1086\/589862","volume":"47","author":"SA Plotkin","year":"2008","unstructured":"Plotkin SA (2008) Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 47(3):401\u2013409","journal-title":"Clin Infect Dis"},{"issue":"10","key":"259_CR72","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/cid\/cit048","volume":"56","author":"SA Plotkin","year":"2013","unstructured":"Plotkin SA (2013) Complex correlates of protection after vaccination. Clin Infect Dis 56(10):1458\u20131465","journal-title":"Clin Infect Dis"},{"issue":"11","key":"259_CR73","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/cis238","volume":"54","author":"SA Plotkin","year":"2012","unstructured":"Plotkin SA, Gilbert PB (2012) Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 54(11):1615\u20131617","journal-title":"Clin Infect Dis"},{"issue":"27","key":"259_CR74","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603\u20132615","journal-title":"N Engl J Med"},{"key":"259_CR75","doi-asserted-by":"crossref","unstructured":"Rahman MM, Zhou N, Huang J (2021) An overview on the development of mRNA-based vaccines and their formulation strategies for improved antigen expression in vivo. Vaccines (Basel) 9(3)","DOI":"10.3390\/vaccines9030244"},{"key":"259_CR76","doi-asserted-by":"crossref","first-page":"251513552090812","DOI":"10.1177\/2515135520908121","volume":"8","author":"S Rajaram","year":"2020","unstructured":"Rajaram S, Boikos C, Gelone DK, Gandhi A (2020) Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing. Ther Adv Vaccines Immunother 8:2515135520908121","journal-title":"Ther Adv Vaccines Immunother"},{"key":"259_CR77","doi-asserted-by":"crossref","unstructured":"Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al (2017) Modified mRNA vaccines protect against Zika virus infection. Cell 168(6):1114\u201325 e10","DOI":"10.1016\/j.cell.2017.02.017"},{"key":"259_CR78","unstructured":"Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine [press release] 22 June 2021"},{"issue":"6","key":"259_CR79","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1189\/jlb.68.6.793","volume":"68","author":"DJ Shedlock","year":"2000","unstructured":"Shedlock DJ, Weiner DB (2000) DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 68(6):793\u2013806","journal-title":"J Leukoc Biol"},{"key":"259_CR81","doi-asserted-by":"crossref","unstructured":"Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L et al (2021a) Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med","DOI":"10.1097\/01.aoa.0000796052.11696.42"},{"issue":"11","key":"259_CR80","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1001\/jama.2021.1967","volume":"325","author":"TT Shimabukuro","year":"2021","unstructured":"Shimabukuro TT, Cole M, Su JR (2021b) Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-14 Dec 2020\u201318 Jan 2021. JAMA 325(11):1101\u20131102","journal-title":"JAMA"},{"key":"259_CR82","doi-asserted-by":"crossref","unstructured":"Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S et al (2021) Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021:2021.07.28.21261159","DOI":"10.1101\/2021.07.28.21261159"},{"key":"259_CR83","doi-asserted-by":"crossref","unstructured":"Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J et al (2021) Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers\u2014Eight U.S. Locations, Dec 2020\u2013Mar 2021. MMWR Morb Mortal Wkly Rep 70(13):495\u2013500","DOI":"10.15585\/mmwr.mm7013e3"},{"issue":"7870","key":"259_CR84","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","volume":"596","author":"JS Turner","year":"2021","unstructured":"Turner JS, O\u2019Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ et al (2021) SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596(7870):109\u2013113","journal-title":"Nature"},{"key":"259_CR85","unstructured":"US Center for Disease Control and Prevention (2021) Safety of COVID-19 Vaccines 2021 [updated 04\/30\/2021. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/safety-of-vaccines.html"},{"key":"259_CR86","doi-asserted-by":"crossref","unstructured":"Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A et al (2020) Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 383(25):2439\u20132450","DOI":"10.1056\/NEJMoa2027906"},{"issue":"5","key":"259_CR87","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/irv.12383","volume":"10","author":"JP Weir","year":"2016","unstructured":"Weir JP, Gruber MF (2016) An overview of the regulation of influenza vaccines in the United States. Influenza Other Respir Viruses 10(5):354\u2013360","journal-title":"Influenza Other Respir Viruses"},{"key":"259_CR88","doi-asserted-by":"crossref","unstructured":"Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M et al (2020) Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med 384(1):80\u201382","DOI":"10.1056\/NEJMc2032195"},{"issue":"23","key":"259_CR89","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","volume":"385","author":"G Witberg","year":"2021","unstructured":"Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y et al (2021) Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med 385(23):2132\u20132139","journal-title":"N Engl J Med"},{"issue":"4949 Pt 1","key":"259_CR90","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","volume":"247","author":"JA Wolff","year":"1990","unstructured":"Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A et al (1990) Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1):1465\u20131468","journal-title":"Science"},{"key":"259_CR91","unstructured":"World Health Organization. Evaluation of the quality, safety and efficacy of messenger RNA vaccines for the prevention of infectious diseases: regulatory considerations 2021 [updated 7 December] Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/ecbs\/post-ecbs-who-regulatory-considerations-document-for-mrna-vaccines---final-version---29-nov-2021_tz.pdf"},{"issue":"6483","key":"259_CR92","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O et al (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367(6483):1260\u20131263","journal-title":"Science"},{"issue":"1","key":"259_CR93","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00431-001-0853-0","volume":"161","author":"O Zent","year":"2002","unstructured":"Zent O, Arras-Reiter C, Broeker M, Hennig R (2002) Immediate allergic reactions after vaccinations\u2014a post-marketing surveillance review. Eur J Pediatr 161(1):21\u201325","journal-title":"Eur J Pediatr"}],"container-title":["Current Topics in Microbiology and Immunology","mRNA Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2022_259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T14:13:08Z","timestamp":1678371188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2022_259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783031180699","9783031180705"],"references-count":92,"URL":"https:\/\/doi.org\/10.1007\/82_2022_259","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"30 July 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}